Suchergebnisse - "Ferro, Alessandra"

PubPharm (26)

1

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients : the challenge is open for new therapeutic strategies

enthalten in: Critical reviews in oncology/hematology | 2024

von Ferro, A. | Marinato, G. | Mulargiu, C. | +4

2

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer : Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

enthalten in: The oncologist | 2024

von Pasello, G. | Lorenzi, M. | Scattolin, D. | +16

3

Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer : a multicentric analysis

enthalten in: Frontiers in immunology | 2024

von Bonanno, L. | Calvetti, L. | Dal Maso, A. | +10

4

Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers : Impact of Multidisciplinary Management in a Real-World Setting

enthalten in: The oncologist | 2024

von Bonanno, L. | Lorenzi, M. | Massa, D. | +15

5

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

enthalten in: Frontiers in immunology | 2024

von Lorenzi, M. | Resi, M. | Bonanno, L. | +5

6

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years : From Radiation Therapy Optimisation to Innovative Systemic Treatments

enthalten in: Cancers | 2022

von Ferro, A. | Sepulcri, M. | Schiavon, M. | +13

7

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC : The BEVERLY Multicenter Randomized Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Piccirillo, M. | Bonanno, L. | Garassino, M. | +30

8

Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer : Pretreatment Predictors and Correlation With Outcome

enthalten in: The oncologist | 2022

von Pavan, A. | Ferro, A. | Fortarezza, F. | +11

9

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer : Outcome and Safety in the Real World: FLOWER Study

enthalten in: The oncologist | 2022

von Lorenzi, M. | Ferro, A. | Cecere, F. | +19

CommentIn: Oncologist. 2022 Mar 4;27(2):79-81. - PMID 35641221

10

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines

enthalten in: Future oncology (London, England) | 2021

von Dal Maso, A. | Lorenzi, M. | Ferro, A. | +17